Inhibition of cGMP phosphodiesterase 5 suppresses serotonin signalling in pulmonary artery smooth muscles cells

Pharmacological Research

Volumn 59, Issue 5, 2009, Pages 312-318

  Li, Manxiang ^a   Sun, Xiuzhen ^a   Li, Zongfang ^a   Liu, Yun ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

ERK1 2; RhoA; Serotonin; Sildenafil; Smooth muscle cells

Indexed keywords

CYCLIC GMP PHOSPHODIESTERASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHODIESTERASE V INHIBITOR; RAS PROTEIN; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SEROTONIN; SILDENAFIL;

ANIMAL CELL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL STIMULATION; CONCENTRATION RESPONSE; DNA SYNTHESIS; DRUG INHIBITION; DRUG MECHANISM; ENZYME INHIBITION; LUNG HEMODYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CYCLIC GMP-DEPENDENT PROTEIN KINASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DNA; ENZYME ACTIVATION; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; PIPERAZINES; PULMONARY ARTERY; PURINES; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SEROTONIN; SIGNAL TRANSDUCTION; SULFONES;

EID: 63549143003     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.01.007     Document Type: Article

References (48)

1. Keegan A., Morecroft I., Smillie D., Hicks M.N., and MacLean M.R. Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. Circ Res 89 (2001) 1231-1239
2. Marcos E., Fadel E., Sanchez O., Humbert M., Dartevelle P., Simonneau G., et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 94 (2004) 1263-1270
3. Dempsie Y., and Maclean M.R. Pulmonary hypertension: therapeutic targets within the serotonin system. Br J Pharmacol 155 (2008) 455-462
4. Eddahibi S., Hanoun N., Lanfumey L., Lesch K.P., Raffestin B., Hamon M., et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 105 (2000) 1555-1562
5. de Caestecker M. Serotonin signaling in pulmonary hypertension. Circ Res 98 (2006) 1229-1231
6. Alapati V.R., McKenzie C., Blair A., Kenny D., MacDonald A., and Shaw A.M. Mechanisms of U46619- and 5-HT-induced contraction of bovine pulmonary arteries: role of chloride ions. Br J Pharmacol 151 (2007) 1224-1234
7. Perez J.F., and Sanderson M.J. The contraction of smooth muscle cells of intrapulmonary arterioles is determined by the frequency of Ca2+ oscillations induced by 5-HT and KCl. J Gen Physiol 125 (2005) 555-567
8. Rodat L., Savineau J.P., Marthan R., and Guibert C. Effect of chronic hypoxia on voltage-independent calcium influx activated by 5-HT in rat intrapulmonary arteries. Pflugers Arch 454 (2007) 41-51
9. Guilluy C., Rolli-Derkinderen M., Tharaux P.L., Melino G., Pacaud P., and Loirand G. Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells. J Biol Chem 282 (2007) 2918-2928
10. Li M., Liu Y., Dutt P., Fanburg B.L., and Toksoz D. Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin. Am J Physiol Lung Cell Mol Physiol 293 (2007) L463-471
11. Lee S.L., Simon A.R., Wang W.W., and Fanburg B.L. H(2)O(2) signals 5-HT-induced ERK MAP kinase activation and mitogenesis of smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 281 (2001) L646-652
12. Chapados R., Abe K., Ihida-Stansbury K., McKean D., Gates A.T., Kern M., et al. ROCK controls matrix synthesis in vascular smooth muscle cells: coupling vasoconstriction to vascular remodeling. Circ Res 99 (2006) 837-844
13. Guignabert C., Izikki M., Tu L.I., Li Z., Zadigue P., Barlier-Mur A.M., et al. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 98 (2006) 1323-1330
14. Izikki M., Hanoun N., Marcos E., Savale L., Barlier-Mur A.M., Saurini F., et al. Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol 293 (2007) L1045-1052
15. Guignabert C., Raffestin B., Benferhat R., Raoul W., Zadigue P., Rideau D., et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 111 (2005) 2812-2819
16. Willers E.D., Newman J.H., Loyd J.E., Robbins I.M., Wheeler L.A., Prince M.A., et al. Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 173 (2006) 798-802
17. Deruelle P., Grover T.R., and Abman S.H. Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. Am J Physiol Lung Cell Mol Physiol 289 (2005) L798-806
18. Pilz R.B., and Casteel D.E. Regulation of gene expression by cyclic GMP. Circ Res 93 (2003) 1034-1046
19. Kirsch M., Kemp-Harper B., Weissmann N., Grimminger F., and Schmidt H.H. Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signalling. FASEB J 22 (2008) 30-40
20. Wharton J., Strange J.W., Moller G.M., Growcott E.J., Ren X., Franklyn A.P., et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 172 (2005) 105-113
21. Tantini B., Manes A., Fiumana E., Pignatti C., Guarnieri C., Zannoli R., et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 100 (2005) 131-138
22. Hemnes A.R., and Champion H.C. Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. Expert Rev Cardiovasc Ther 4 (2006) 293-300
23. Murray F., MacLean M.R., and Pyne N.J. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 137 (2002) 1187-1194
24. Ghofrani H.A., Osterloh I.H., and Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 5 (2006) 689-702
25. Herrera E.A., Ebensperger G., Krause B.J., Riquelme R.A., Reyes R.V., Capetillo M., et al. Sildenafil reverses hypoxic pulmonary hypertension in highland and lowland newborn sheep. Pediatr Res 63 (2008) 169-175
26. Larrue B., Jaillard S., Lorthioir M., Roubliova X., Butrous G., Rakza T., et al. Pulmonary vascular effects of sildenafil on the development of chronic pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 288 (2005) L1193-1200
27. Galie N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
28. Golovina V.A., and Blaustein M.P. Preparation of primary cultured mesenteric artery smooth muscle cells for fluorescent imaging and physiological studies. Nat Protoc 1 (2006) 2681-2687
29. Li M., Zacharia J., Sun X., and Wier W.G. Effects of siRNA knock-down of TRPC6 and InsP(3)R1 in vasopressin-induced Ca(2+) oscillations of A7r5 vascular smooth muscle cells. Pharmacol Res 58 (2008) 308-315
30. Loirand G., Guerin P., and Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 98 (2006) 322-334
31. Homma N., Nagaoka T., Morio Y., Ota H., Gebb S.A., Karoor V., et al. Endothelin-1 and serotonin are involved in activation of RhoA/Rho kinase signaling in the chronically hypoxic hypertensive rat pulmonary circulation. J Cardiovasc Pharmacol 50 (2007) 697-702
32. Ying Z., Jin L., Palmer T., and Webb R.C. Angiotensin II up-regulates the leukemia-associated Rho guanine nucleotide exchange factor (RhoGEF), a regulator of G protein signaling domain-containing RhoGEF, in vascular smooth muscle cells. Mol Pharmacol 69 (2006) 932-940
33. Li M., Li Z., and Sun X. Statins suppress MMP2 secretion via inactivation of RhoA/ROCK pathway in pulmonary vascular smooth muscles cells. Eur J Pharmacol 591 (2008) 219-223
34. Wang Z., Jin N., Ganguli S., Swartz D.R., Li L., and Rhoades R.A. Rho-kinase activation is involved in hypoxia-induced pulmonary vasoconstriction. Am J Respir Cell Mol Biol 25 (2001) 628-635
35. Broughton B.R., Walker B.R., and Resta T.C. Chronic hypoxia induces Rho kinase-dependent myogenic tone in small pulmonary arteries. Am J Physiol Lung Cell Mol Physiol 294 (2008) L797-806
36. Sawada N., Itoh H., Ueyama K., Yamashita J., Doi K., Chun T.H., et al. Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 101 (2000) 2030-2033
37. Liu Y., Suzuki Y.J., Day R.M., and Fanburg B.L. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res 95 (2004) 579-586
38. Zhao M., Discipio R.G., Wimmer A.G., and Schraufstatter I.U. Regulation of CXCR4-mediated nuclear translocation of extracellular signal-related kinases 1 and 2. Mol Pharmacol 69 (2006) 66-75
39. McNamara P.J., Murthy P., Kantores C., Teixeira L., Engelberts D., van Vliet T., et al. Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide. Am J Physiol Lung Cell Mol Physiol 294 (2008) L205-213
40. Wojciak-Stothard B., Tsang L.Y., Paleolog E., Hall S.M., and Haworth S.G. Rac1 and RhoA as regulators of endothelial phenotype and barrier function in hypoxia-induced neonatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 290 (2006) L1173-1182
41. Sawada N., Itoh H., Yamashita J., Doi K., Inoue M., Masatsugu K., et al. cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem Biophys Res Commun 280 (2001) 798-805
42. Ellerbroek S.M., Wennerberg K., and Burridge K. Serine phosphorylation negatively regulates RhoA in vivo. J Biol Chem 278 (2003) 19023-19031
43. Preston I.R., Hill N.S., Warburton R.R., and Fanburg B.L. Role of 12-lipoxygenase in hypoxia-induced rat pulmonary artery smooth muscle cell proliferation. Am J Physiol Lung Cell Mol Physiol 290 (2006) L367-374
44. Yang X., Long L., Southwood M., Rudarakanchana N., Upton P.D., Jeffery T.K., et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 96 (2005) 1053-1063
45. Yamboliev I.A., and Gerthoffer W.T. Modulatory role of ERK MAPK-caldesmon pathway in PDGF-stimulated migration of cultured pulmonary artery SMCs. Am J Physiol Cell Physiol 280 (2001) C1680-1688
46. Cheng T.H., Shih N.L., Chen S.Y., Lin J.W., Chen Y.L., Chen C.H., et al. Nitric oxide inhibits endothelin-1-induced cardiomyocyte hypertrophy through cGMP-mediated suppression of extracellular-signal regulated kinase phosphorylation. Mol Pharmacol 68 (2005) 1183-1192
47. Rolli-Derkinderen M., Sauzeau V., Boyer L., Lemichez E., Baron C., Henrion D., et al. Phosphorylation of serine 188 protects RhoA from ubiquitin/proteasome-mediated degradation in vascular smooth muscle cells. Circ Res 96 (2005) 1152-1160
48. Kass D.A., Champion H.C., and Beavo J.A. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 101 (2007) 1084-1095